» Articles » PMID: 24568560

Acquired Defects in CFTR-dependent β-adrenergic Sweat Secretion in Chronic Obstructive Pulmonary Disease

Overview
Journal Respir Res
Specialty Pulmonary Medicine
Date 2014 Feb 27
PMID 24568560
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Smoking-induced chronic obstructive pulmonary disease (COPD) is associated with acquired systemic cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction. Recently, sweat evaporimetry has been shown to efficiently measure β-adrenergic sweat rate and specifically quantify CFTR function in the secretory coil of the sweat gland.

Objectives: To evaluate the presence and severity of systemic CFTR dysfunction in smoking-related lung disease using sweat evaporimetry to determine CFTR-dependent sweat rate.

Methods: We recruited a cohort of patients consisting of healthy never smokers (N = 18), healthy smokers (12), COPD smokers (25), and COPD former smokers (12) and measured β-adrenergic sweat secretion rate with evaporative water loss, sweat chloride, and clinical data (spirometry and symptom questionnaires).

Measurements And Main Results: β-adrenergic sweat rate was reduced in COPD smokers (41.9 ± 3.4, P < 0.05, ± SEM) and COPD former smokers (39.0 ± 5.4, P < 0.05) compared to healthy controls (53.6 ± 3.4). Similarly, sweat chloride was significantly greater in COPD smokers (32.8 ± 3.3, P < 0.01) and COPD former smokers (37.8 ± 6.0, P < 0.01) vs. healthy controls (19.1 ± 2.5). Univariate analysis revealed a significant association between β-adrenergic sweat rate and female gender (β = 0.26), age (-0.28), FEV1% (0.35), dyspnea (-0.3), and history of smoking (-0.27; each P < 0.05). Stepwise multivariate regression included gender (0.39) and COPD (-0.43) in the final model (R()2 = 0.266, P < 0.0001).

Conclusions: β-adrenergic sweat rate was significantly reduced in COPD patients, regardless of smoking status, reflecting acquired CFTR dysfunction and abnormal gland secretion in the skin that can persist despite smoking cessation. β-adrenergic sweat rate and sweat chloride are associated with COPD severity and clinical symptoms, supporting the hypothesis that CFTR decrements have a causative role in COPD pathogenesis.

Citing Articles

Inflammation in the COVID-19 airway is due to inhibition of CFTR signaling by the SARS-CoV-2 spike protein.

Caohuy H, Eidelman O, Chen T, Mungunsukh O, Yang Q, Walton N Sci Rep. 2024; 14(1):16895.

PMID: 39043712 PMC: 11266487. DOI: 10.1038/s41598-024-66473-4.


Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL).

Baker E, Harris W, Guimbellot J, Bliton K, Rowe S, Raju S J Cyst Fibros. 2024; 23(5):959-966.

PMID: 39033068 PMC: 11410542. DOI: 10.1016/j.jcf.2024.07.010.


An Adverse Outcome Pathway for Decreased Lung Function Focusing on Mechanisms of Impaired Mucociliary Clearance Following Inhalation Exposure.

Luettich K, Sharma M, Yepiskoposyan H, Breheny D, Lowe F Front Toxicol. 2022; 3:750254.

PMID: 35295103 PMC: 8915806. DOI: 10.3389/ftox.2021.750254.


Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunction.

Kaza N, Lin V, Stanford D, Hussain S, Libby E, Kim H Eur Respir J. 2021; 60(1).

PMID: 34916262 PMC: 10079430. DOI: 10.1183/13993003.01581-2021.


Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine.

Carrasco-Hernandez L, Quintana-Gallego E, Calero C, Reinoso-Arija R, Ruiz-Duque B, Lopez-Campos J Biomedicines. 2021; 9(10).

PMID: 34680554 PMC: 8533244. DOI: 10.3390/biomedicines9101437.


References
1.
Quinton P, Molyneux L, Ip W, Dupuis A, Avolio J, Tullis E . β-adrenergic sweat secretion as a diagnostic test for cystic fibrosis. Am J Respir Crit Care Med. 2012; 186(8):732-9. DOI: 10.1164/rccm.201205-0922OC. View

2.
Maestrelli P, Saetta M, Mapp C, Fabbri L . Remodeling in response to infection and injury. Airway inflammation and hypersecretion of mucus in smoking subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164(10 Pt 2):S76-80. DOI: 10.1164/ajrccm.164.supplement_2.2106067. View

3.
Garcia-Rio F, Miravitlles M, Soriano J, Munoz L, Duran-Tauleria E, Sanchez G . Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res. 2010; 11:63. PMC: 2891677. DOI: 10.1186/1465-9921-11-63. View

4.
Hammond K, Turcios N, Gibson L . Clinical evaluation of the macroduct sweat collection system and conductivity analyzer in the diagnosis of cystic fibrosis. J Pediatr. 1994; 124(2):255-60. DOI: 10.1016/s0022-3476(94)70314-0. View

5.
Rabe K, Hurd S, Anzueto A, Barnes P, Buist S, Calverley P . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176(6):532-55. DOI: 10.1164/rccm.200703-456SO. View